Skip directly to content

Pfizer Canada Statement: Alesse 21 and Alesse 28 Product Complaints

02/12/17

KIRKLAND (Quebec) – December 2, 2017 – Pfizer Canada is working with Health Canada to determine the nature and scope of the issue. We will continue to monitor the situation and assess the need for further action. Pfizer Canada will update consumers and health care professionals as appropriate.

Pfizer is committed to ensuring the safety and quality of our medicines.  Every complaint received by the organization is investigated and, when available, complaint samples are retrieved and analyzed. Pfizer takes patient safety very seriously and takes action if patient safety is at risk.

For more information, please contact:
Pfizer Canada Media Line: 1-866-9Pfizer (1 866 973-4937)
[email protected]